SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is trending due to a significant stock drop following news that its NHS-Galleri cancer screening trial in the UK missed a primary endpoint, sparking intense debate between bears who see further downside and bulls who view the sell-off as an overreaction, pointing to strong financials and US market performance.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is surging as its all-stock acquisition of Valaris creates an offshore drilling giant with a massive backlog and anticipated synergies, driving community excitement for a potential short squeeze and significant re-rating in a robust energy market.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following a dual announcement: a $100 million non-dilutive royalty funding agreement and a simultaneous $100 million public offering. The community is sharply divided, with many expressing frustration over perceived dilution and management's choices, while others view the moves as strategic to unlock credit, secure financial runway, and strengthen the company's negotiating position for its pipeline assets.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as a recent corporate presentation highlighted significant anticipated distribution and shelf space growth for its brands, further bolstered by positive comments from a key strategic partner regarding collaboration and market execution. While many in the community are optimistic about continued sales expansion, others express frustration over recent stock volatility and perceived management communication challenges.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending following an earnings report that showcased robust revenue growth but also a net loss driven by increased credit loss provisions and an unclear path to profitability. This has polarized the community, with many calling the significant share price drop an overreaction to underlying growth, while others condemn the BNPL model as unsustainable amidst rising credit risks.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to its recent earnings report, which highlighted strong revenue growth and significant investments for future expansion despite a net loss, coupled with a major patent extension until 2042 and the initiation of a new IBSRELA clinical trial, all fueling community speculation about a potential acquisition by Zydus Lifesciences.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont Corp is trending following an earnings beat that surpassed revenue and EPS expectations, yet its stock performance is mixed as the community debates a more conservative 2026 production outlook. Despite strong financial results and a bullish sentiment around gold's record prices, investors are weighing future output guidance against the company's current performance and the broader precious metals rally.

AIOS Foundation

AIOS is trending due to its recent ticker change from NISN and a substantial after-hours volume surge, sparking widespread community discussion about its potential for a 'gap fill' setup as a 'China penny play,' despite some expressing caution regarding its financial history and recent private placement.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is rallying on a strong Q4 earnings beat, an increased dividend, and a favorable capital expenditure outlook, with community discussions also centered on geopolitical tensions impacting oil prices and the company's ongoing debt reduction strategy.

Akamai Technologies, Inc. engages in the provision of cloud services for delivering, optimizing, and securing content and business applications over the Internet. Its products include security, web performance, media delivery, and network operator. The company was founded by Frank T. Leighton, Jonathan Seelig, Randall S. Kaplan, and Daniel M. Lewin on August 20, 1998 and is headquartered in Cambridge, MA.

Akamai Technologies Inc

Akamai Technologies is trending after a mixed earnings report showing a beat on Q4 estimates but significantly weaker-than-expected forward guidance. The community is actively debating its strategic pivot into high-growth AI and edge computing, with some seeing it as an undervalued AI infrastructure play amidst strong security and cloud segment performance, while others remain bearish due to the soft outlook and ongoing challenges in its traditional CDN business.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2030 Earnings Forecast for SGMO Issued By HC Wainwright

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a report issued on Tuesday...

Sangamo Therapeutics (NASDAQ:SGMO) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen downgraded shares of Sangamo Therapeutics to a "strong sell" rating in a report on Saturday...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Hold" from Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been given a consensus recommendation of "Hold" by the seven ratings firms that are presently covering the firm, MarketBeat Ratings...

Sangamo Therapeutics (NASDAQ:SGMO) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Sangamo Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Saturday...

Research Analysts Offer Predictions for SGMO FY2025 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright decreased their FY2025 earnings per share estimates for Sangamo Therapeutics in a report released on Monday, November 10th. HC...

Q4 Earnings Forecast for SGMO Issued By HC Wainwright

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their Q4 2025 earnings estimates for shares of Sangamo Therapeutics in a note issued to investors on Monday, November...

Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus...

Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -266.67% and -98.84%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

What Makes Sangamo (SGMO) a New Buy Stock

Sangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

SGMO
Sangamo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMO News

SGMOSangamo Therapeutics Inc